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Type 2 diabetes is a risk factor for Alzheimer’s disease (AD). Previously, we have shown 
that the diabetes drug liraglutide is protective in middle aged and in old APP/PS1 mice. 
Here, we show that liraglutide has prophylactic properties. When injecting liraglutide 
once-daily ip. in two months old mice for 8 months, the main hallmarks of AD were much 
reduced. Memory formation in object recognition and Morris water maze were 
normalised and synapse loss and the loss of synaptic plasticity was prevented. In addition, 
amyloid plaque load, including dense core congophilic plaques, was much reduced. 
Chronic inflammation (activated microglia) was also reduced in the cortex, and 
neurogenesis was enhanced in the dentate gyrus. The results demonstrate that liraglutide 
may protect from progressive neurodegeneration that develops in AD. The drug is 








Type 2 diabetes has been identified as a risk factor for Alzheimer’s disease (Luchsinger, 
Tang, Shea, & Mayeux, 2004; Ohara et al., 2011), presumably linked to an impairment in 
insulin signalling in the brain. In the brains of people with Alzheimer’s disease, insulin 
signalling was found to be much impaired, even independently of a medical history of 
diabetes (Moloney et al., 2010; Talbot et al., 2012). The incretin hormone Glucagon like 
peptide-1 (GLP-1) facilitates insulin signalling, and long-lasting GLP-1 analogues such as 
Liraglutide (Victoza®) are on the market as diabetes therapies (Lovshin & Drucker, 
2009). Liraglutide crosses the blood-brain barrier and increases synaptic plasticity 
(Hunter & Holscher, 2012; P. L. McClean, Gault, Harriott, & Holscher, 2010). Liraglutide 
and other GLP-1 mimetics have been found to be neuroprotective in a range of 
neurodegenerative disorders (Holscher, 2013; Perry & Greig, 2005). 
        We reported previously that liraglutide treatment improved cognitive function, 
reduced amyloid plaque deposition, inflammation, overall amyloid precursor protein 
(APP) and amyloid oligomer levels and enhanced long-term potentiation of synaptic 
transmission (LTP) in the hippocampus in 9 months old APPswe/PS1 ∆E9 (APP/PS1) 
mice that had been treated for 8 weeks (P. McClean, Parthsarathy, Faivre, & Hölscher, 
2011). At this stage, animals had already developed amyloid plaques and the first synaptic 
and memory impairments, comparable to patients in the early stage of Alzheimer’s 
disease. Liraglutide also reversed disease progression in 16 months old APP/PS1 mice 
that had been treated for two months. Liraglutide significantly improved recognition and 
spatial memory, reduced beta amyloid plaque load, total APP and aggregated beta 
amyloid levels and chronic inflammation in the brain (P. L. McClean & Holscher, 2014). 
At 14 months, the amyloid plaque load of APP/PS1 mice had increased to maximum 
levels, and damage in the brain had already been established.  
Insulin signalling is impaired in the brain of this APP/PS1 mouse model, similar to the 
insulin signalling impairment observed in the human brain (Bomfim et al., 2012). 
Importantly, liraglutide has been shown to prevent this insulin de-sensitisation in the 
brain, as well as an ability to reverse some of the insulin signalling impairments in human 
AD brain tissue in an ex vivo assay (Talbot et al., 2011). 
         The current study was designed to elucidate if liraglutide has a prophylactic  effect 
when administered before plaque deposition and associated memory impairments are 
present in the APP/PS1 model. Animals were treated from 8 weeks of age onwards for 8 
months once-daily at the previously established effective dose (P. McClean et al., 2011).  
 
2. Materials and Methods 
 
2.1 Animals 
APPswe/PS1∆E9 mice with a C57Bl/6 background were bred at the animal unit of the 
University of Ulster. Heterozygous males were bred with wild-type C57/Bl6 females 
bought locally (Harlan, UK). Offspring were ear punched and genotyped using PCR with 
primers specific for the APP-sequence (Forward “GAATTCCGACATGACTCAGG”, 
Reverse: “GTTCTGCTGCATCTTGGACA”). For details see (Gengler, Hamilton, & 
Holscher, 2010). Mice not expressing the transgene were used as wild-type controls. Male 
animals were used in all studies. Animals were caged individually and maintained on a 
12/12 light-dark cycle (lights on at 08h00, off at 20h00), in temperature-controlled room 
(T:21.5°C±1). Food and water were available ad libitum. Animals were handled daily for 
two weeks prior to commencement of the study.  
APP/PS1 and wild-type animals were 8 weeks of age when treatment began. Mice 
were randomized and had blood glucose measured before initiation of their designated 
treatment, liraglutide (25 nm/kg bw) or saline (0.9% w/v). Liraglutide and saline were 
made up to a final volume of 10ml/kg, with 0.9% saline used as vehicle for liraglutide and 
were injected intraperitoneally (i.p.) once daily (at 15:00h).  Treatment groups comprised 
n =12. All experiments were licensed by the UK home office in accordance with the 
Animal (scientific procedures) Act of 1986. 
  
2.2 Peptides 
Liraglutide was purchased from GL Biochem Ltd. (Shanghai). The purity of the 
peptide was analysed by reversed-phase HPLC and characterised using matrix assisted 
laser desorption/ionisation time of flight (MALDI-TOF) mass spectrometry, with a purity 
> 99%.  
 Peptides were reconstituted in ultrapure® water to a concentration of 1 mg/ml in 
polypropylene tubes and frozen in aliquots to permit fresh preparation of doses required 
for injection. 
 
2.3 Blood glucose measurement 
Blood glucose was measured from tail vein blood blood by an automated glucose oxidase 
procedure using the Ascencia® Contour® Blood Glucose Meter and corresponding 
analysis strips (Bayer Healthcare, Berkshire, UK). 
 
2.4 Object recognition task 
The object recognition task was conducted in a grey-coloured aluminium open-field arena 
(58cm in diameter; 31cm high wall) as previously described (Abbas, Faivre, & Hölscher, 
2009). Objects for exploration were red cubes (1.8cm diameter) and white balls (2.6cm 
diameter). The arena and objects were cleaned with 70% ethanol between trials to prevent 
the build-up of olfactory cues.  
Mice received a session of 5min in the empty open-field, 24h prior to exposure to 
objects, in order to habituate them to the apparatus and test room.  Motor activity was 
recorded by total path, number of lines crossed, and speed. The number of rearing events 
(forepaws elevated from the floor) was considered to be an index of exploratory 
behaviour. The number of grooming sessions and the number of fecal pellets were 
recorded as measures of anxiety in mice. 
Twenty-four hours after habituation, each mouse was subject to a 10min 
acquisition trial, during which they were placed in the open-field in presence of two 
identical objects (cube or ball) situated at 15cm from the arena wall. After a 3h retention 
interval, the mice were placed back into the arena and exposed to the familiar object and 
to a novel object for a further 10min. Object location and novel and familiar objects were 
randomized throughout the trial.  
Total time spent exploring each of the two objects (when the animal’s snout was 
directly toward the object at a distance ≤2cm), was recorded. Recognition index was 
defined as the amount of time exploring the novel object over the total time spent 
exploring both objects multiplied by 100, and was used to measure recognition memory 
(TB/(TA + TB))*100 where A represents familiar object and B, novel object. Object 
recognition data from all groups was analysed by student t-test for each group, to compare 
time spent exploring the familiar object to time spent exploring the novel object. Animals 
were injected for 8 months prior to, and received their injection as normal at 3pm on the 
day prior to open field and object recognition tasks, which were commenced at 9am to 
avoid acute drug effects.  
 
2.5 Morris Water maze task 
The maze was made of white opaque plastic with a diameter of 120cm and 40 cm high 
walls, and was filled with water at 25ºC to avoid hypothermia. A small escape platform 
(10 x 6.5 x 21.5 cm) was placed at a fixed position in the centre of one quadrant, 25cm 
from the perimeter, and was hidden 1cm beneath the water surface. The room contained a 
number of fixed visual cues on the walls. 
Acquisition phase: The acquisition trial phase consisted of 4 training days (Day1-
4) and four trials per day with a 15-min inter-trial interval. Four points equally spaced 
along the circumference of the pool (North, South, East, West) served as the starting 
position, which was randomised across the four trials each day. If an animal did not reach 
the platform within 90s, it was guided to the platform where it had to remain for 30s, 
before being returned to its home cage. Mice were kept dry, between trials, in a plastic 
holding cage filled with paper towels. The path length and escape latencies were recorded 
(n=12 per group). 
Probe Trial- One day after finishing the acquisition task (Day 5), a probe trial was 
performed in order to assess the spatial memory (after a 24h delay). The platform was 
removed from the maze and animals were allowed to swim freely for 60s. Time spent in 
the target quadrant was assessed, as was spatial acuity, which measured the amount of 
time spent in the exact area where the escape platform had been located. 
 
Reversal Morris Water maze task 
One day after completion of the Morris water maze task, a reversal training programme 
commenced. This involved changing the location of the escape platform and a 3-day 
acquisition phase, followed by a probe trial on day 4 (conducted as outlined above; n=12 
per group). 
 
2.6 Surgery and LTP recording in the hippocampus area CA1 
Mice were anesthetized with urethane (ethyl carbamate, 1.8g/kg ip.) for the 
duration of all experiments. The skull was exposed and 3 holes with 0.8mm diameter 
were drilled. Electrodes (tungsten with Teflon coating, Bilaney, Kent, United Kingdom) 
were implanted, 1.5mm posterior and 1.0mm lateral to the midline for the recording 
electrode, and 2.0mm posterior to bregma and 1.5mm lateral to the midline for the 
stimulating electrode. The electrodes were slowly lowered through the cortex and the 
upper layers of the hippocampus and into the CA1 region until the appearance of a 
negative deflecting excitatory postsynaptic potential (EPSP) that had a latency of ca 
10msec. Recordings of field excitatory postsynaptic potentials (fEPSPs) were made from 
the stratum radiatum in the CA1 region of the right hippocampal hemisphere in response 
to stimulation of the Schaffer collateral/commissural pathway. fEPSPs were recorded on a 
computerized stimulating and recording unit (PowerLab, ADI Instruments) in which the 
trigger threshold was adjustable. The triggered unit activated a constant current stimulus 
isolation unit (Neurolog, United Kingdom). The data acquisition system was triggered 
simultaneously to record all events. Sampling speed was at 20kHz for recordings of 
fEPSPs. In order to assess the excitability and determine an appropriate voltage for high 
frequency stimulation and recording, the response of each of the mouse to increasing 
voltage was measured in an input/output curve at intervals of 0.25 V from 2.0 V to a 
maximum of 5 V (or until a maximal response was elicited). Stimulation voltage was then 
adjusted to generate approximately 60% of the maximum fEPSP, and the recording of the 
baseline was measured at this value. The high frequency stimulation protocol for inducing 
LTP consisted of 4 trains of 100 stimuli with an interstimulus interval of 5msec (200Hz) 
and an inter-train interval of 2 sec. This LTP induction protocol was chosen to prevent 
saturation of LTP and thus allow the possibility to detect facilitation of LTP in the 
APP/PS1 mice. LTP was measured as a percentage of baseline fEPSP slope recorded over 
a 15-minute period before application of high frequency stimulation. This value was taken 
as 100% of the excitatory postsynaptic potential slope and all recorded values were 
normalized to this baseline value. The post high frequency stimulation LTP data were 
then analysed by a two-way repeated measures ANOVA with treatment group as the 
between subject factor and time as the within subject factor. 
Paired-pulse facilitation (PPF) was measured to analyse pre-synaptic functions 
and interneuron activity. Two stimuli were given at 60% of max fEPSP response. The 
interval between two stimuli was changed from 25ms to 50, 80, 120, 160 and 200ms to 
analyse PPF in relation to time. PPF induced at short interstimulus intervals is considered 
to be triggered by pre-synaptic transmitter release facilitating processes (Chen, Chad, & 
Wheal, 1996) while later PPF is considered to be linked to GABAa (80-120msec) and 
GABAb (160-200msec) inter-neuronal synaptic transmission (Schulz, Cook, & Johnston, 
1995; Tsai, Shen, & Leung, 2008). The size of the fEPSP response was measured by 
analysing the change from baseline to the lowest point of the fEPSP. Data were 
normalised by taking the first fEPSP value as 100% and comparing the second fEPSP 
with it. The normalised PPF values were then analysed by two-way repeated measures 




After the LTP studies, animals were perfused trans-cardially with PBS buffer followed by 
ice-cold 4% paraformaldehyde in PBS. Brains were removed and fixed in 4% 
paraformaldehyde for at least 24h before being transferred to 30% sucrose solution 
overnight. Brains were then snap frozen using EnvirofreezTM and coronal sections of 40-
micron thickness were cut at a depth of -2 to -3 Bregma using a Leica cryostat. Sections 
were chosen according to stereological rules (Bondolfi et al., 2002) with the first section 
taken at random and every 6th section afterwards.  
Staining was carried out for Iba-1, a marker for activated microglia to measure the 
inflammation response (Paresce, Chung, & Maxfield, 1997), beta-amyloid plaques, and 
for congophilic dense-core amyloid plaques. Staining was also carried out for 
synaptophysin, in order to determine synapse numbers, and Doublecortin (DCX), a 
marker for immature neurons, as a measure of neurogenesis. All sections were incubated 
in 3% H2O2 to quench endogenous peroxidase activity. For Iba1 staining, sections were 
incubated in 0.05M trisodium citrate (pH 9) at 90oC for 30 minutes to enhance antigen 
recognition. After blocking the sections in 5% normal serum to avoid non-specific 
antibody binding, they were incubated with rabbit polyclonal anti ionized calcium binding 
adaptor molecule 1 (Iba1) (1:2000, Wako, Germany, 016-20001) or rabbit polyclonal anti 
amyloid beta peptide (1:250, Invitrogen, UK, 71-5800) as shown in (Radde et al., 2006) 
or goat polyclonal anti doublecortin (1:200, Santacruz, USA, sc-710), or rabbit anti-
synaptophysin (1:200, Abcam, Cambridge, MA, 7837-500). After overnight incubation at 
4oC, the sections were incubated in respective secondary antibodies. For visualisation 
Vectastain Elite and SG substrate (Vector laboratories, Burlingame, CA, USA) were used. 
Congo red staining for congophilic plaques was carried out as described by (Wilcock, 
Gordon, & Morgan, 2006). All staining was visualized by Axio Scope 1 (Zeiss, Germany) 
and analysis of percentage stained area was conducted for plaque load, dense core plaques 
and inflammation. The percentage stained area of each image (2 images per section, 
approximately 8-10 sections per mouse, 16-20 images total) was quantified using a multi 
threshold plug in with Image J (NIH, USA). N=12 per group.   
 
2.8 Statistics 
Data were analysed using the program Prism (Graphpad software Inc., USA), with the 
level of probability set at 95%. Results are expressed as means ± standard error of the 
mean (SEM). Data were analyzed by 1-way or 2-way ANOVA, followed by post hoc 




3.1 Chronic 8 month injection has no impact on bodyweight, plasma glucose and 
general behaviour in wild-type and APP/PS1 mice in the open field 
Bodyweight of mice was comparable among all groups throughout the duration of the 
study, with no significant differences observed between groups. APP/PS1 saline 
21.4±0.8g (start) 30.6±0.8g (end), APP/PS1 liraglutide 22.0±0.6g (start) 28.6±0.7g (end), 
Wild-type saline 22.2±0.3g (start), 30.4±1.0g (end). In line with this, a 2-way repeated 
measures ANOVA demonstrated that fasted plasma glucose concentrations were not 
significantly altered by long-term administration of liraglutide, with no significant 
treatment effect observed. APP/PS1 saline 6.3±0.2mmol/L (start) 5.2±0.1 mmol/L (end), 
APP liraglutide 6.0±0.2 mmol/L (start) 5.1±0.3 mmol/L (end), Wild-type saline 5.7±0.2 
mmol/L (start), 5.0±0.3 mmol/L (end).  
APP/PS1 mice were injected once-daily with saline or 25nmol/kg liraglutide i.p., 
while wild-type mice were injected with saline for 8 months prior to exposure to the open 
field arena. In a one-way ANOVA, despite such long-term injection no significant 
difference was observed in path length (A; F=0.99; p>0.05), speed (B; F=0.75; p>0.05), 
number of line crosses (C; F=0.87; p>0.05), exploratory behaviour (D; F=0.38; p>0.05), 
number of grooming episodes (E; F=2.58; p>0.05) or amount of time spent in the centre 
vs. periphery of the arena (F; F=2.62; p>0.05) between groups. This indicates that anxiety 
levels and locomotor activity are not affected by long-term administration of liraglutide in 
APP/PS1 mice (Figure. 1).   
 
3.2 Liraglutide treatment maintains recognition memory in APP/PS1 mice 
In a two way ANOVA of object recognition data there was a significant preference for 
novel object location in APP/PS1 liraglutide (t=4.28, p<0.001) and wild-type saline-
treated mice (t=2.78; p<0.05), but not APP/PS1 saline-treated mice (t=1.3; p>0.05). 
Illustrated in Figure 2 (upper) are the recognition indices for novel and familiar objects 
and results of a student t-tests per treatment. The object recognition task was conducted at 
10 months of age after 8 months saline or liraglutide. Wild-type saline-treated mice 
demonstrated a significant preference for novel object (A; t=3.3; p=0.004). Saline-treated 
APP/PS1 mice failed to discriminate novel and familiar object (B; t=0.89; p>0.05), while 
APP/PS1 mice treated with 25nmol/kg liraglutide demonstrated a strong preference for 
novel object (C; t=3.6; p=0.0016), indicating recognition memory is preserved by the 
drug. Looking at the difference scores between groups, a one-way ANOVA, demonstrates 
there is a significant difference overall (Figure 2D; F=5.0; p=0.014). Bonferroni post hoc 
analysis shows that there was a significant difference between the APP/PS1 liraglutide 
and APP/PS1 saline-treated groups (Figure 2D;t=3.1; p<0.05). 
 
3.3 Liraglutide treatment improves Morris water maze performance in APP/PS1 
mice 
In a Morris water maze task APP/PS1-saline treated mice performed significantly worse 
than wild-type saline and APP/PS1 liraglutide-treated mice overall (Figure 2 E,F,G). 
Escape latency significantly decreased over time (2E; F=46.91; P<0.0001). Acquisition, 
as analysed by 2-way repeated measures ANOVA, was significantly different between 
treatment groups (F=3.28; p<0.05), however in bonferroni post hoc tests, escape latency 
of APP/PS1 saline treated mice was significantly greater than that of wild-type saline-
treated mice on day 1 (Figure 2E; t=3.5; p<0.01). In a probe trial (Figure 2F, the wild-type 
saline (t=2.7; p<0.05), and APP/PS1 liraglutide-treated mice (t=4.78; p<0.001) spent 
significantly more time than expected by chance (25%) in the target quadrant, while 
APP/PS1 saline-treated mice did not. Moreover, APP/PS1 saline-treated mice spent 
significantly less time in the target quadrant than the APP/PS1 liraglutide-treated group 
(Figure 2F; t=3.7; p<0.05). Spatial acuity was analysed by assessing the amount of time 
spent exactly where the escape platform was located during training. The performance of 
liraglutide-treated APP/PS1 mice was comparable with their wild-type counterparts, with 
both groups performing significantly better that the APP/PS1 saline-treated group (Figure 
2G; f=2.8 and 2.6 respectively; p<0.05).  
In the acquisition phase of the reversal water maze task (Figure 2H), liraglutide-
treated APP/PS1 mice performed similarly to wild-type mice, and significantly better than 
the APP/PS1 saline group. Escape latency decreased over time (F=53.5; p<0.0001), and a 
significant group effect was observed (F=3.8; p=0.025). In the reversal probe trial the 
APP/PS1 saline-treated group spent significantly less time in the target quadrant than the 
APP/PS1 liraglutide-treated group (Figure 2I; t=3.2; p<0.05). There were no significant 
differences in spatial acuity between groups in the reversal probe trial (Figure 2F).  
 
3.4 Liraglutide enhances LTP in APP/PS1 mice 
When testing the inducibility of LTP in the hippocampus in vivo, using a weak 
stimulation protocol, saline-treated wild-type mice induced weak LTP, saline-treated 
APP/PS1 animals were unable to induce LTP, while the APP/PS1 liraglutide-treated 
group showed enhanced LTP (Figure 3A; overall 2-way repeated measures ANOVA of 
post HFS baseline demonstrated a significant group effect p=0.012, F=5.72). There was 
no significant difference between wild-type saline and APP/PS1 liraglutide-treated groups 
(p=0.09, F=3.38), or wild-type saline and APP/PS1 saline treated groups (p=0.11, 
F=3.07). However comparing post-HFS baseline of APP/PS1 saline and APP/PS1 
liraglutide groups, there was a significant drug effect (p=0.013, F=8.395).  
 Analysing the final 15 minutes of recordings by 2-way repeated measures 
ANOVA also demonstrated a significant group effect p=0.026, F=4.52). There was no 
significant difference between wild-type saline and APP/PS1 liraglutide-treated groups 
(p=0.10, F=3.14), or wild-type saline and APP/PS1 saline treated groups (p=0.26, 
F=1.43). However comparing the final 15 minutes of post-HFS recordings of APP/PS1 
saline and APP/PS1 liraglutide groups, there was a significant drug effect (p=0.02, 
F=7.1).  
Paired-pulse facilitation was comparable between wild-type and both groups of 
APP/PS1 mice at 25, 50, 80, 160 and 200ms (Figure 3B). 
 
3.5 Histological hallmarks of Alzheimer’s disease are dramatically reduced in the 
cortex and in area CA1 of liraglutide-treated APP/PS1 mice 
In 10 months old APP/PS1 mice, after 8 months treatment with 0.9% saline or liraglutide 
(25 nm/kg bw), there was a 40% reduction in plaque load of in the cortex of liraglutide-
treated APP/PS1 mice (Figure 4 A-C; p<0.001). Furthermore, the percentage area stained 
positively for dense-core Congo-red plaques was reduced by 59% with liraglutide 
treatment (Figure 4 D-F;  p<0.001). The inflammatory response in the cortex, as measured 
by number of activated microglia (IBA-1 stain), was also reduced by 50% in the 
liraglutide-treated group, in line with the reductions observed in plaque load (The P value 
is < 0.0001,  F = 82.41, DFn=2, DFd=187, For the interaction: P value is 0.9797, F = 
0.4314, DFn=18, DFd=187, Figure 4 G-I). In comparison, wt brains showed very low 
levels of inflammation in comparison with APP/PS1 mice that were injected with saline 
or liraglutide (Figure 4 I; p<0.0001). Additionally the number of young neurons 
(doublecortin-positive cells) in the dentate gyrus was increased by 61% by liraglutide, 
normalising cell proliferation compared to wt brain tissue (The P value is < 0.0001,  F = 
23.55, DFn=2, DFd=98, For the interaction: P value is 0.1592, F = 1.478, DFn=10, 
DFd=98, Figure 4 J-L).  
 
In the area CA1, the plaque load was reduced by 45% in liraglutide-treated APP/PS1 mice 
(p<0.001; Figure 5A-C). The Congo red-positive dense core plaque load was reduced by 
64% (p<0.001; Figure 5D-F). The inflammatory response, as shown by activated 
microglia staining (Iba-1), was decreased by 47% with liraglutide treatment (The P value 
is < 0.0001, F = 227.94, DFn=2, DFd=186; For the interaction: P value is 0.0008, F = 
3.208, DFn=10, DFd=186; Figure 5G-I). In comparison, wt brains showed very low levels 
of inflammation in comparison with APP/PS1 mice that were injected with saline or 
liraglutide (Figure 5 I; p<0.0001). Data analysed by regular two-way ANOVA (not 
repeated measures) with Bonferroni post-hoc test, n=6. 
 
3.6 Synaptophysin levels are increased in Liraglutide-treated APP/PS1 mice 
Representative micrographs of synaptophysin staining in APP/PS1 saline (A, D), 
APP/PS1 liraglutide (B, E), and wild-type saline (C, F) mice are illustrated in Figure 6. 
Quantification of levels of expression of synaptophysin demonstrates that wild-type 
saline–treated mice had significantly higher expression levels than APP/PS1 saline-
treated mice in all brain regions studied (Figure 6 G-N; p<0.05-p<0.0001). APP/PS1 
liraglutide-treated mice, meanwhile, had comparable density of synaptophysin staining as 
wild-type mice in the polymorph layer (Figure G), granule cell layer (Figure H), 
molecular layer (Figure I) and stratum pyramidale (Figure K), but significantly reduced 
levels in stratum radiatum (P<0.01, Figure J), stratum oriens (P<0.0001, Figure L), 
interior (P<0.0001, Figure M), and exterior cortex (P<0.0001, Figure N), when compared 
to the wild-type mice.  Statistics for the treatment effect (column factor in the ANOVA 
analysis) for each layer: polymorph layer (The P value is < 0.0001,  F = 45.60, DFn=2, 
DFd=88, Figure 5 G), granule cell layer (The P value is 0.0011,  F = 7.388, DFn=2, 
DFd=89, Figure 5 H), molecular layer (The P value is < 0.0001,  F = 16.60, DFn=2, 
DFd=89, Figure 5 I), stratum radiatum (The P value is < 0.0001,  F = 43.96, DFn=2, 
DFd=90, Figure 5 J), stratum pyramidale (The P value is 0.0006,  F = 8.046, DFn=2, 
DFd=90, Figure 5 K), stratum oriens (The P value is < 0.0001,  F = 71.77, DFn=2, 
DFd=90, Figure 5 L), interior cortex (The P value is < 0.0001,  F = 56.05, DFn=2, 
DFd=90, Figure 5 M), exterior cortex (The P value is < 0.0001,  F = 32.15, DFn=2, 
DFd=90, Figure 5 N).  
Statistics for the interaction: polymorph layer (The P value is 0.6155,  F = 0.8144, 
DFn=10, DFd=88, Figure 5 G), granule cell layer (The P value is 0.0179,  F = 2.317, 
DFn=10, DFd=89, Figure 5 H), molecular layer (The P value is 0.6527,  F = 0.7746, 
DFn=10, DFd=89, Figure 5 I), stratum radiatum (The P value is 0.4965,  F = 0.9452, 
DFn=10, DFd=90, Figure 5 J), stratum pyramidale (The P value is 0.9458,  F = 0.3948, 
DFn=10, DFd=90, Figure 5 K), stratum oriens (The P value is 0.3376,  F = 1.146, 
DFn=10, DFd=90, Figure 5 L) interior cortex (The P value is 0.1614,  F = 1.105, DFn=10, 
DFd=90, Figure 5 M).  exterior cortex (The P value is 0.1614,  F = 1.476, DFn=10, 
DFd=90, Figure 5 N). Overall, APP/PS1 liraglutide-treated animals had significantly 
higher expression levels than saline-treated APP/PS1 mice in all layers of the 
hippocampus (Figure 6G-L), as well as the interior (M) and exterior (N) cortex, indicating 
that liraglutide has a protective effect on synapse numbers. Data analysed by regular two-






The results show that liraglutide  treatment, initiated before amyloid plaque deposition 
and memory impairments are apparent significantly reduces histological and behavioural  
biomarkers of AD in the APP/PS1 mouse model. Notably similar improvements were 
observed when treatment was initiated after memory impairments and significant amyloid 
plaque load are apparent (P. McClean et al., 2011), indicating prophylactic administration 
does not appear to offer additional benefits in this transgenic model of AD. When testing 
the general behaviour in the open field, no overt changes in motor activity, exploration or 
anxiety could be detected. Liraglutide has been on the market as a treatment for diabetes 
in Europe since 2009 (Davies, Kela, & Khunti, 2011). It is a safe and well-tolerated drug 
with few side effects. An initial report that GLP-1 mimetics may enhance the likelihood 
of developing pancreatitis or even pancreatic cancer has not been confirmed in a 
subsequent large scale analysis (EMA, 2013; Roy et al., 2014; Sadry & Drucker, 2013). 
Therefore, this drug is considered safe and can be taken safely over a long period of time. 
Recently, liraglutide has been licenced as a weight-loss drug under the brand name 
Saxenda® and is safe to be taken by people who are not diabetic (Wadden et al., 2013), 
which is an important finding with respect to its potential use in normoglycaemic 
Alzheimer’s disease patients. 
In our study, chronic drug treatment that started before the onset of amyloid plaque 
formation and the associated neurodegenerative processes showed good effects. In the 
object recognition and Morris water maze memory tests, drug treated APP/PS1 mice 
performed as well as littermate wild type mice, while saline treated APP/PS1 mice 
demonstrated impairments in both recognition and spatial memory. This clear result was 
also reflected in the enhancement of long-term potentiation of synaptic activity in the 
hippocampus (LTP). The saline treated APP/PS1 mice failed to develop stable LTP, while 
drug treated APP/PS1 mice were able to express strong LTP that was superior to that of 
littermate controls. When quantifying synapse numbers in the cortex and hippocampus, 
we demonstrated that there was a substantial loss of synapses in the saline treated 
APP/PS1 mice. This loss was prevented to some degree by liraglutide treatment. Synapse 
loss is commonly observed in human AD brains (Robinson et al., 2014). This loss of 
connections between neurons is most likely the reason for the loss of cognitive function in 
AD patients. The preservation of memory formation and the demonstration of healthy 
LTP in the hippocampus in the APP/PS1 mice show promise that liraglutide may protect 
the brain from this synaptic deterioration. The results reported here are comparable to our 
study of the effects of liraglutide in middle-aged APP/PS1 mice that already showed first 
signs of AD pathology and amyloid build-up before initiation of treatment (P. McClean et 
al., 2011) and aged mice that have established AD pathology and a high amyloid plaque 
load (P. L. McClean & Holscher, 2014). 
In the current study, long-term liraglutide treatment greatly reduced the formation of 
amyloid plaques. The Congo red positive crystalised amyloid core plaque load was more 
significantly reduced than overall plaque load. As these dense-core amyloid plaques are 
considered to induce the inflammation response (Saura, 2010), this result is of great 
interest. The formation of amyloid plaques was not completely prevented with chronic 
liraglutide treatment, however, one has to keep in mind that this transgenic mouse model 
of AD expresses human mutated APP in an unregulated way (Jankowsky et al., 2001). 
The expression of APP in such a model cannot be regulated as is in wild-type mice. APP 
expression is modulated by several factors, so that it may be possible that in humans, APP 
gene expression in the brain may be reduced by this drug (Kovacs et al., 1995). The 
current observation that there are still moderately high levels of amyloid plaques found in 
the brain should be interpreted with caution. GLP-1 signalling modulates BACE1 and 
alpha-secretase expression and activity. Previous research has shown that amyloid 
formation is reduced by a shift from beta- to alpha-secretase processing of APP (Ohtake, 
Saito, Eto, & Seki, 2014; Perry et al., 2003). This process may explain the reduced 
amyloid levels found here. 
In line with reduced plaque load, the chronic inflammation response, as measured in 
levels of activated microglia, was concurrently and significantly reduced. Chronic 
inflammation has detrimental effects on the brain and is an important part of chronic 
neurodegenerative disorders (Holmes et al., 2009; Najem, Bamji-Mirza, Chang, Liu, & 
Zhang, 2014). Neurogenesis was also found to be normalised in the dentate gyrus of 
APP/PS1 mice. The impairment of neurogenesis is an indication that growth factor 
signalling is reduced in the brains of these animals, and pro-inflammatory cytokines have 
been shown to inhibit this process (Lee, Han, Nam, Oh, & Hong, 2010). Chronic 
treatment with liraglutide reversed this impairment, demonstrating that growth signalling 
has been normalised. We have previously shown that liraglutide reduces the chronic 
inflammation response and the associated release of pro-inflammatory cytokines 
(Parthsarathy & Holscher, 2013). GLP-1 is a growth factor, and activation of GLP-1 
receptors activates second messenger cell signalling pathways that enhance gene 
expression, reduce apoptosis, normalise energy utilisation and cell proliferation (Li, 
Tweedie, Mattson, Holloway, & Greig, 2010; Sharma, Jalewa, & Holscher, 2013). 
Growth factor signalling has been shown to be impaired in the brains of AD patients 
(Moloney et al., 2010; Talbot et al., 2012) and in APP/PS1 mice (Long-Smith et al., 
2013), and the treatment with GLP-1 receptor agonists normalised this (Bomfim et al., 
2012; Isacson et al., 2011; Long-Smith et al., 2013).  The normalisation of growth factor 
signalling will normalise the repair and growth processes in neurons, including the 
normalisation of energy metabolism and synaptogenesis (Holscher, 2014). 
In conclusion, the study presented here supports the concept that liraglutide or similar 
GLP-1 mimetics have prophylactic effects and reduce Alzheimer’s disease progression in 
the APP/PS1 mouse model. Our previous study in middle-aged mice demonstrated that 
liraglutide has protective effects at a stage where the disease has already advanced to a 
stage where the first behavioural symptoms appear (P. McClean et al., 2011). The drug 
also showed some improvement in aged APP/PS1 mice which represent the late stage of 
AD (P. L. McClean & Holscher, 2014), raising hopes that liraglutide may show some 
positive effects even in the later stages of Alzheimer’s disease. We also showed in a 
separate study that the extensive vascular pathology induced by the high expression of 
amyloid in the APP/PS1 mouse model could be ameliorated by liraglutide (Kelly et al., 2015). As vascular pathology plays an important role in AD, this drug effect may be an 
important factor in the overall protective drug effect. Other studies also report good 
neuroprotective effects of liraglutide in a different mouse model of AD.  In the 
senescence-accelerated mouse prone 8 (SAMP8) mouse model, liraglutide significantly 
enhanced memory formation and also protected from neuronal loss in area CA1 (Hansen et al., 2015). 
Our data add to the growing evidence base demonstrating GLP-1 mimetics are 
neuroprotective (Holscher, 2013). Several GLP-1 mimetics such as Exendin-4, liraglutide 
and lixisenatide are licenced as treatments for type 2 diabetes (Campbell & Drucker, 
2013), and this facilitates the testing of these drugs in clinical trials of neurodegenerative 
diseases. A clinical trial of exendin-4 in Parkinson patients had been conducted as a proof 
of concept in a randomised open label trial. Drug treated patients showed improvement at 
12 months in motor tasks, compared with decline in control patients. Most interestingly, 
exendin-4 showed a clear improvement in the Mattis DRS-2 cognitive score, suggesting 
that exendin-4 has beneficial effects on cognition (Aviles-Olmos et al., 2013). This effect 
was still measurable 12 months after the clinical trial had finished (Aviles-Olmos et al., 
2014). A larger study using a double blind randomised design is currently ongoing.  
In addition, based on the encouraging preclinical effects that we found with liraglutide, a 
pilot study testing liraglutide in AD patients had been conducted. In a double- blind 
placebo controlled trial lasting 6 months, the placebo group showed a decline in brain 
activity and energy metabolism as shown in 18FGD-PET imaging. The liraglutide treated 
group showed no decline at all, and even displayed a tendency of improvement over 
baseline. The 18FGD-PET signal correlates well with cognitive impairment, synaptic 
dysfunction and general disease progression (Gejl et al., 2015). This result is a proof of 
concept that the data obtained in animal studies translate to human patients. A phase II 
clinical trial testing liraglutide in MCI/AD patients has started at Imperial College London 
(clinical trial identifier NCT01843075). This trial will deliver more detailed information 
on how liraglutide affects or improves the disease progression of AD.  
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 FIGURE LEGENDS 
 
Figure 1:  
Open field observation of 10 month old liraglutide treated APP/PS1 mice, compared 
with saline-injected APP/PS1 and wild-type mice treated for 8 months, beginning at 
8 weeks of age. APP/PS1 mice were injected once-daily with saline or 25nmol/kg 
liraglutide, while wild-type mice were injected with saline for 8 months prior to exposure 
to the open field arena. Long-term treatment had no impact on motor activity or anxiety 
measures, as no significant difference was observed in path length (A), speed (B), number 
of line crosses (C), exploratory behaviour (D), number of grooming episodes (E) or 
amount of time spent in the centre vs. periphery of the arena (F) between all groups. 
(n=12 per group).   
 
Figure 2:  
Top: Recognition memory is preserved in liraglutide-treated APP/PS1 mice.  
The object recognition task was conducted, in 10 month old mice, after 8 months daily 
treatment of APP/PS1 mice with either 0.9% saline or liraglutide (25nm/kg bw). Their 
performance was compared with wild-type mice injected with saline for 8 months, which 
served as a control. In the task two identical objects were shown to mice for 10min. After 
a 3h interval mice were exposed to one novel and one familiar object. Shown is the 
recognition index (RI), which is the % time spent exploring the novel object vs. the 
overall exploration time. Wild-type mice demonstrated a significant preference for novel 
object (A). Saline-treated APP/PS1 mice failed to discriminate novel and familiar object 
(B), while APP/PS1 mice treated with 25nmol/kg liraglutide demonstrated a strong 
preference for novel object (C). Overall difference scores were significantly reduced in 
the APP/PS1 saline-treated group compared with the APP/PS1 liraglutide treated group 
(D). **p<0.01 vs. familiar object, Δp<0.05 vs. APP/PS1 liraglutide group, n=12 per 
group. 
Bottom: Liraglutide treatment improves Morris water maze performance in 
APP/PS1 mice 
The Morris water maze task was conducted in 10 month old APP/PS1 mice, after 8 
months treatment with 0.9% saline or Liraglutide (25nm/kg bw). Their performance was 
compared with control wild-type mice injected with saline. Mice were exposed to a 
Morris water maze learning paradigm involving 4 days acquisition, followed by a probe 
trial. Mice then received 3 days reversal training (with platform location moved) followed 
by a reversal probe trial. Escape latency of APP/PS1 saline treated mice was significantly 
greater than that of wild-type saline-treated mice on day 1 (E). In the probe trial (F), wild-
type saline and APP/PS1 liraglutide-treated mice performed better than the APP/PS1 
saline group. In fact the liragltide APP/PS1 group spent significantly more time in the 
target quadrant than the saline-treated APP/PS1 group (F). Spatial acuity of wild-type 
saline and APP/PS1 liraglutide groups was significantly better than the APP/PS1 saline-
treated group (C).  
Escape latencies of liraglutide-treated APP/PS1 mice and wild-type mice were 
significantly faster than the APP/PS1 saline group the reversal water maze task (H). In the 
reversal probe trial the APP/PS1 saline-treated group spent significantly less time in the 
target quadrant than the APP/PS1 liraglutide-treated group (G). There were no significant 
differences in spatial acuity between groups in the reversal probe trial (H). *p<0.05, 
***p<0.001 vs chance (25%). Δp<0.05,vs. APP/PS1 liraglutide, Οp<0.05 vs wild-type 
saline. N=12 per group 
 
Figure 3: Liraglutide enhances LTP in APP/PS1 mice 
Liraglutide, injected chronically for 8 months protected and potentiated the induction and 
maintenance of LTP in the CA1 of the hippocampus in APP/PS1 mice when compared 
with APP/PS1 saline-treated mice, who failed to induce LTP (A). Paired-pulse facilitation 
was comparable between wild-type and both groups of APP/PS1 at 50, 80, 160 and 
200ms (B). N=9-12 per group. 
 
Figure 4: Histological hallmarks of Alzheimer’s disease are improved by liraglutide 
treatment. After chronic 8 month treatment with 0.9% saline or liraglutide (25nm/kg bw) 
the number of plaques in the cortex of liraglutide-treated APP/PS1 mice was reduced by 
40% (A, B, C). The number of Congo-red positive dense core plaques was reduced by 
59% (D, E, F). The inflammatory response, as shown by activated microglia (IBA-1stain), 
was also halved (G, H, I). Mice treated with liraglutide also had a significant increase in 
neurogenesis (Doublecortin positive cells) compared with saline-treated animals (J, K, L). 
Wild type brain sections are shown for comparison (split panels H, K, graph I, L). Sample 
micrographs are shown. ***P<0.001 vs APP/PS1 saline-treated group, n=6 per group. 
 
Figure 5: Plaque load and inflammation in the CA1 are reduced with chronic 
liraglutide treatment. 
After chronic 8 month treatment with 0.9% saline or liraglutide (25nm/kg bw) the number 
of plaques in the CA1 of liraglutide-treated APP/PS1 mice was reduced by 45% (A, B, 
C). The number of Congo-red positive dense core plaques was reduced by 63% (D, E, F), 
and the inflammatory response, as shown by activated microglial load (IBA-1stain), was 
reduced by 47% (G, H, I). Wild type IBA-1 data are shown for comparison (split panel H, 
graph I). Sample micrographs are shown. ***p<0.0001 vs APP/PS1 saline-treated group 
n=6. 
 
Figure 6: Synaptophysin levels are partially restored by Liraglutide treatment in 
APP/PS1 mice Representative hippocampal images of synaptophysin-stained brains of  
APP/PS1 saline (A, B), APP/PS1 liraglutide (C, D) and wild-type saline (E, F) mice are 
shown. In each image the layers of the hippocampus are numbered as 1: Polymorph layer, 
2: Granule cell layer, 3: Molecular layer, 4: Stratum radiatum, 5: Stratum pyramidale, 6: 
Stratum oriens 
Quantification of levels of expression of synaptophysin in each of the layers, 
Polymorph layer (G), Granule cell layer (H), Molecular layer (I), Stratum radiatum (J), 
Stratum pyramidale (K), Stratum oriens (L), as well as interior cortex (M), and exterior 
cortex (N) demonstrates that wild-type animals had significantly higher expression levels 
in all regions analysed than both saline and Liraglutide-treated APP/PS1 mice. Liraglutide 
increased hippocampal and cortical synaptophysin levels in APP/PS1 mice. *p<0.05, 
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